Childhood Vaccines Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023
Global Childhood Vaccines Market
Vaccines are the biological preparations which provide the active acquired immunity to the particular disease. Generally, the vaccines contain a substance that resembles the disease causing agent, and is prepared from killed or weakened form of microbe, its toxin or its surface proteins. Agents present in the vaccines stimulate the immune system of the body for recognition of the agent as foreign so that the body’s immune system can easily recognize and destroy any of these microorganisms that it later encounters. Childhood vaccines are commonly administered to the age group of 3-8 years which may include DPT vaccine for Diphtheria, Pertussis, and Tetanus, Hepatitis, Influenza, and Measles vaccines, among others.
The global childhood vaccines market is expanding at robust CAGR due to increase in the birth rate. Increase in the awareness regarding vaccination of various diseases in developed countries, initiations took by various government and non-governmental organizations such as World Health Organization (WHO), and Centre for Disease Control and Prevention (CDC), and growth in adoption of vaccines fuel the childhood vaccines market growth over the forecast period. Furthermore, government insurance and reimbursement scenario, low cost of vaccines, development of new vaccines for various diseases, and an increase in the healthcare expenditure might boost the global childhood vaccines market growth over the forecast period. However, adverse effects associated with the vaccines, stringent regulatory policies, and lack of awareness regarding the diseases and vaccination in low-income countries might hamper the growth of childhood vaccines market over the forecast period.
The childhood vaccines market is segmented on the basis of vaccine type, route of administration applications, and end-user
Based on vaccine type, the childhood vaccines market has been segmented into the following:
Inactivated Vaccines
Attenuated Vaccines
Toxoid Vaccines
Subunit Vaccines
Conjugate Vaccines
Others
Based on the route of administration, the childhood vaccines market has been segmented into the following:
Oral
Intramuscular
Intradermal
Subcutaneous
Intranasal
Based on the application, the childhood vaccines market has been segmented into the following:
Diphtheria
Pertussis
Tetanus
Polio
Measles
Hepatitis-B
Others
Based on the composition, the childhood vaccines market has been segmented into the following:
Mono vaccines
Combination vaccines
Based on the end-user, the childhood vaccines market has been segmented into the following:
Hospitals
Clinics
Vaccination Centres
Nowadays, the global childhood vaccines market is in the mature stage, competitors are focusing on the development of new vaccines for various diseases. Increase in the prevalence of various diseases such as measles, hepatitis, diphtheria, and among others might fuel the growth of childhood vaccines market. Acquisitions & mergers, collaborations, launch of new products, and technological developments are some of the key strategies followed by various companies for increasing their share in the global childhood vaccines market over the forecast period. For instance, in January 2011, Sanofi Pasteur has inked a licensing deal with Germany’s Organobalance that gives Sanofi access to a modified yeast strain for use in vaccines. Similarly, in October 2014, MabVax Therapeutics Holdings, Inc., announced that the FDA has granted an orphan drug designation to the Company’s vaccine intended for the treatment of the childhood cancer neuroblastoma. In addition, in January 2013 GSK, Biological E partner on childhood vaccine to produce a 6-in-1 vaccine to protect against polio and 5 other diseases. The innovation of single vaccine for multiple diseases might fuel the global childhood vaccines market growth over the forecast period.
Geographically, the childhood vaccines market has been segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. U.S. childhood vaccines market is expected to dominate the North America regional revenue share over the coming years due to burgeoning awareness levels and adoption of state-of-art technologies to the production of vaccines. North America holds the largest share attributed to increase in the prevalence of various diseases such as pertussis (In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S), measles, and hepatitis etc. In addition, increase in the R&D of vaccines, rise in the healthcare expenditure, and favourable reimbursement scenario might fuel the childhood vaccines market growth in the North America region. Europe childhood vaccines market holds a dominant share owing to increase in the awareness of vaccination regarding various diseases. For instance, France made that vaccination is mandatory from 2018 because of children are dying of measles (according to the European Centre for Disease Prevention and Control, there were 79 cases of measles reported in France in the first two months of 2017). Increase in the healthcare expenditure and research and development activities boost the market in the Europe. Asia-Pacific is an emergent market for childhood vaccines due to increase in the birth rate, especially in India and China. Increase in adoption for vaccination, and growth in the prevalence of infectious disease might fuel the childhood vaccines market growth in Asia-Pacific over the forecast period. Due to less cost of vaccines, Latin America and the Middle East and Africa also hold a significant share in childhood vaccination market.
Some of the players in childhood vaccines market are MedImmune (U.S.), Johnson & Johnson Services Inc., (U.S.), Merck & Co., Inc. (U.S.), Sanofi (France), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (U.S.), Astellas Pharma (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), GlaxoSmithKline plc, (U.K.), Protein Sciences Corporation (U.S.), Novartis AG (Switzerland), Organobalance GMBH (Germany), Biological E (India), and Mabvax Therapeutics Holdings Inc. (U.S.) to name a few.
In June 2017, Takeda and BE collaborate to develop low-cost vaccines for low and middle-income countrie
In April 2017, Serum Institute of India Pvt. Ltd., acquired Nanotherapeutics for the development of polio vaccine
In January 2017, FDA approved Sanofi Pasteur’s active immunization against tetanus, diphtheria, poliomyelitis, and pertussis in children 4 to 6 years of age
Vaccines are the biological preparations which provide the active acquired immunity to the particular disease. Generally, the vaccines contain a substance that resembles the disease causing agent, and is prepared from killed or weakened form of microbe, its toxin or its surface proteins. Agents present in the vaccines stimulate the immune system of the body for recognition of the agent as foreign so that the body’s immune system can easily recognize and destroy any of these microorganisms that it later encounters. Childhood vaccines are commonly administered to the age group of 3-8 years which may include DPT vaccine for Diphtheria, Pertussis, and Tetanus, Hepatitis, Influenza, and Measles vaccines, among others.
The global childhood vaccines market is expanding at robust CAGR due to increase in the birth rate. Increase in the awareness regarding vaccination of various diseases in developed countries, initiations took by various government and non-governmental organizations such as World Health Organization (WHO), and Centre for Disease Control and Prevention (CDC), and growth in adoption of vaccines fuel the childhood vaccines market growth over the forecast period. Furthermore, government insurance and reimbursement scenario, low cost of vaccines, development of new vaccines for various diseases, and an increase in the healthcare expenditure might boost the global childhood vaccines market growth over the forecast period. However, adverse effects associated with the vaccines, stringent regulatory policies, and lack of awareness regarding the diseases and vaccination in low-income countries might hamper the growth of childhood vaccines market over the forecast period.
The childhood vaccines market is segmented on the basis of vaccine type, route of administration applications, and end-user
Based on vaccine type, the childhood vaccines market has been segmented into the following:
Inactivated Vaccines
Attenuated Vaccines
Toxoid Vaccines
Subunit Vaccines
Conjugate Vaccines
Others
Based on the route of administration, the childhood vaccines market has been segmented into the following:
Oral
Intramuscular
Intradermal
Subcutaneous
Intranasal
Based on the application, the childhood vaccines market has been segmented into the following:
Diphtheria
Pertussis
Tetanus
Polio
Measles
Hepatitis-B
Others
Based on the composition, the childhood vaccines market has been segmented into the following:
Mono vaccines
Combination vaccines
Based on the end-user, the childhood vaccines market has been segmented into the following:
Hospitals
Clinics
Vaccination Centres
Nowadays, the global childhood vaccines market is in the mature stage, competitors are focusing on the development of new vaccines for various diseases. Increase in the prevalence of various diseases such as measles, hepatitis, diphtheria, and among others might fuel the growth of childhood vaccines market. Acquisitions & mergers, collaborations, launch of new products, and technological developments are some of the key strategies followed by various companies for increasing their share in the global childhood vaccines market over the forecast period. For instance, in January 2011, Sanofi Pasteur has inked a licensing deal with Germany’s Organobalance that gives Sanofi access to a modified yeast strain for use in vaccines. Similarly, in October 2014, MabVax Therapeutics Holdings, Inc., announced that the FDA has granted an orphan drug designation to the Company’s vaccine intended for the treatment of the childhood cancer neuroblastoma. In addition, in January 2013 GSK, Biological E partner on childhood vaccine to produce a 6-in-1 vaccine to protect against polio and 5 other diseases. The innovation of single vaccine for multiple diseases might fuel the global childhood vaccines market growth over the forecast period.
Geographically, the childhood vaccines market has been segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. U.S. childhood vaccines market is expected to dominate the North America regional revenue share over the coming years due to burgeoning awareness levels and adoption of state-of-art technologies to the production of vaccines. North America holds the largest share attributed to increase in the prevalence of various diseases such as pertussis (In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S), measles, and hepatitis etc. In addition, increase in the R&D of vaccines, rise in the healthcare expenditure, and favourable reimbursement scenario might fuel the childhood vaccines market growth in the North America region. Europe childhood vaccines market holds a dominant share owing to increase in the awareness of vaccination regarding various diseases. For instance, France made that vaccination is mandatory from 2018 because of children are dying of measles (according to the European Centre for Disease Prevention and Control, there were 79 cases of measles reported in France in the first two months of 2017). Increase in the healthcare expenditure and research and development activities boost the market in the Europe. Asia-Pacific is an emergent market for childhood vaccines due to increase in the birth rate, especially in India and China. Increase in adoption for vaccination, and growth in the prevalence of infectious disease might fuel the childhood vaccines market growth in Asia-Pacific over the forecast period. Due to less cost of vaccines, Latin America and the Middle East and Africa also hold a significant share in childhood vaccination market.
Some of the players in childhood vaccines market are MedImmune (U.S.), Johnson & Johnson Services Inc., (U.S.), Merck & Co., Inc. (U.S.), Sanofi (France), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (U.S.), Astellas Pharma (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), GlaxoSmithKline plc, (U.K.), Protein Sciences Corporation (U.S.), Novartis AG (Switzerland), Organobalance GMBH (Germany), Biological E (India), and Mabvax Therapeutics Holdings Inc. (U.S.) to name a few.
In June 2017, Takeda and BE collaborate to develop low-cost vaccines for low and middle-income countrie
In April 2017, Serum Institute of India Pvt. Ltd., acquired Nanotherapeutics for the development of polio vaccine
In January 2017, FDA approved Sanofi Pasteur’s active immunization against tetanus, diphtheria, poliomyelitis, and pertussis in children 4 to 6 years of age
1. EXECUTIVE SUMMARY
2. GLOBAL CHILDHOOD VACCINES MARKET INTRODUCTION
2.1. Global Childhood Vaccines Market – Taxonomy
2.2. Global Childhood Vaccines Market –Definitions
2.2.1. Vaccine Type
2.2.2. Application
2.2.3. Application
2.2.4. Composition
2.2.5. End-User
3. GLOBAL CHILDHOOD VACCINES MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Childhood Vaccines Market Dynamic Factors - Impact Analysis
3.6. Global Childhood Vaccines Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.7. Global Childhood Vaccines Market –Trends
4. GLOBAL CHILDHOOD VACCINES MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL CHILDHOOD VACCINES MARKET, BY TREATMENT TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. Inactivated Vaccines
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Attenuated Vaccines
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Toxoid Vaccines
5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Subunit Vaccines
5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Conjugate Vaccines
5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. GLOBAL CHILDHOOD VACCINES MARKET, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
6.1. Oral
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Intramuscular
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Intradermal
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Subcutaneous
6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Intranasal
6.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. GLOBAL CHILDHOOD VACCINES MARKET, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
7.1. Diphtheria
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Pertussis
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Tetanus
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Polio
7.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Measles
7.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Hepatitis-B
7.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.6.3. Market Opportunity Analysis
7.7. Others
7.7.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.7.3. Market Opportunity Analysis
8. GLOBAL CHILDHOOD VACCINES MARKET FORECAST, BY COMPOSITION, 2012 - 2016 AND FORECAST, 2017 – 2023
8.1. Mono Vaccines
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Combination Vaccines
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
9. GLOBAL CHILDHOOD VACCINES MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023
9.1. Hospitals
9.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Clinics
9.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Vaccination Centres
9.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
10. GLOBAL CHILDHOOD VACCINES MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1. North America
10.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.1.3. Market Opportunity Analysis
10.2. Europe
10.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.2.3. Market Opportunity Analysis
10.3. Asia-Pacific
10.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.3.3. Market Opportunity Analysis
10.4. Latin America
10.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.4.3. Market Opportunity Analysis
10.5. Middle East and Africa
10.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.5.3. Market Opportunity Analysis
10.6. Global Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Region, 2017 – 2023
11. NORTH AMERICA CHILDHOOD VACCINES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1. Vaccine Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Inactivated Vaccines
11.1.2. Attenuated Vaccines
11.1.3. Toxoid Vaccines
11.1.4. Subunit Vaccines
11.1.5. Conjugate Vaccines
11.1.6. Others
11.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Oral
11.2.2. Intramuscular
11.2.3. Intradermal
11.2.4. Subcutaneous
11.2.5. Intranasal
11.3. Application Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Diphtheria
11.3.2. Pertussis
11.3.3. Tetanus
11.3.4. Polio
11.3.5. Measles
11.3.6. Hepatitis-B
11.3.7. Others
11.4. Composition Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Mono Vaccines
11.4.2. Combinition Vaccines
11.5. End-User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Vaccination Centres
11.6. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.6.1. U.S.
11.6.2. Canada
11.7. North America Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2017 – 2023
11.8. North America Childhood Vaccines Market Dynamics – Trends
12. EUROPE CHILDHOOD VACCINES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1. Vaccine Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Inactivated Vaccines
12.1.2. Attenuated Vaccines
12.1.3. Toxoid Vaccines
12.1.4. Subunit Vaccines
12.1.5. Conjugate Vaccines
12.1.6. Others
12.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Oral
12.2.2. Intramuscular
12.2.3. Intradermal
12.2.4. Subcutaneous
12.2.5. Intranasal
12.3. Application Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Diphtheria
12.3.2. Pertussis
12.3.3. Tetanus
12.3.4. Polio
12.3.5. Measles
12.3.6. Hepatitis-B
12.3.7. Others
12.4. Composition Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Mono Vaccines
12.4.2. Combinition Vaccines
12.5. End-User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Vaccination Centres
12.6. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.6.1. Germany
12.6.2. UK
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Russia
12.6.7. Poland
12.6.8. Rest of Europe
12.7. Europe Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2017 – 2023
12.8. Europe Childhood Vaccines Market Dynamics – Trends
13. ASIA-PACIFIC CHILDHOOD VACCINES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
13.1. Vaccine Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Inactivated Vaccines
13.1.2. Attenuated Vaccines
13.1.3. Toxoid Vaccines
13.1.4. Subunit Vaccines
13.1.5. Conjugate Vaccines
13.1.6. Others
13.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Oral
13.2.2. Intramuscular
13.2.3. Intradermal
13.2.4. Subcutaneous
13.2.5. Intranasal
13.3. Application Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Diphtheria
13.3.2. Pertussis
13.3.3. Tetanus
13.3.4. Polio
13.3.5. Measles
13.3.6. Hepatitis-B
13.3.7. Others
13.4. Composition Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Mono Vaccines
13.4.2. Combinition Vaccines
13.5. End-User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Vaccination Centres
13.6. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. ASEAN
13.6.5. Australia & New Zealand
13.6.6. Rest of Asia-Pacific
13.7. Asia-Pacific Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2017 – 2023
13.8. Asia-Pacific Childhood Vaccines Market Dynamics – Trends
14. LATIN AMERICA CHILDHOOD VACCINES MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
14.1. Vaccine Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Inactivated Vaccines
14.1.2. Attenuated Vaccines
14.1.3. Toxoid Vaccines
14.1.4. Subunit Vaccines
14.1.5. Conjugate Vaccines
14.1.6. Others
14.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Oral
14.2.2. Intramuscular
14.2.3. Intradermal
14.2.4. Subcutaneous
14.2.5. Intranasal
14.3. Application Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Diphtheria
14.3.2. Pertussis
14.3.3. Tetanus
14.3.4. Polio
14.3.5. Measles
14.3.6. Hepatitis-B
14.3.7. Others
14.4. Composition Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Mono Vaccines
14.4.2. Combinition Vaccines
14.5. End-User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Vaccination Centres
14.6. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Argentina
14.6.4. Venezuela
14.6.5. Rest of Latin America
14.7. Latin America Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2017 – 2023
14.8. Latin America Childhood Vaccines Market Dynamics – Trends
15. MIDDLE EAST AND AFRICA CHILDHOOD VACCINES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
15.1. Vaccine Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
15.1.1. Inactivated Vaccines
15.1.2. Attenuated Vaccines
15.1.3. Toxoid Vaccines
15.1.4. Subunit Vaccines
15.1.5. Conjugate Vaccines
15.1.6. Others
15.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.2.1. Oral
15.2.2. Intramuscular
15.2.3. Intradermal
15.2.4. Subcutaneous
15.2.5. Intranasal
15.3. Application Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.3.1. Diphtheria
15.3.2. Pertussis
15.3.3. Tetanus
15.3.4. Polio
15.3.5. Measles
15.3.6. Hepatitis-B
15.3.7. Others
15.4. Composition Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.4.1. Mono Vaccines
15.4.2. Combinition Vaccines
15.5. End-User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Vaccination Centres
15.6. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
15.6.1. Gulf Cooperation Council (GCC) Countries
15.6.2. Israel
15.6.3. South Africa
15.6.4. Rest of MEA
15.7. MEA Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2017 – 2023
15.8. MEA Childhood Vaccines Market Dynamics – Trends
16. COMPETITION LANDSCAPE
16.1. Strategic Dashboard of Top Market Players
16.2. Company Profiles (Introduction, Financial Analysis, Treatment Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
16.2.1. AstraZeneca (UK)
16.2.2. Bayer AG (Germany)
16.2.3. Daiichi Sankyo Company Ltd (Japan)
16.2.4. Eisai Co Ltd (Japan)
16.2.5. GlaxoSmithKline Plc. (UK)
16.2.6. Grupo Praxis Pharmaceutical SA (Spain)
16.2.7. KaloBios Pharmaceuticals, Inc. (U.S.)
16.2.8. Kancera AB (Sweden)
16.2.9. Novartis AG (Switzerland)
16.2.10. Laboratorio Elea S.A.C.I.F. y A (Argentina)
16.2.11. Oblita Therapeutics BVBA (Belgium)
16.2.12. Sanofi (France
17. RESEARCH METHODOLOGY
18. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL CHILDHOOD VACCINES MARKET INTRODUCTION
2.1. Global Childhood Vaccines Market – Taxonomy
2.2. Global Childhood Vaccines Market –Definitions
2.2.1. Vaccine Type
2.2.2. Application
2.2.3. Application
2.2.4. Composition
2.2.5. End-User
3. GLOBAL CHILDHOOD VACCINES MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Childhood Vaccines Market Dynamic Factors - Impact Analysis
3.6. Global Childhood Vaccines Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.7. Global Childhood Vaccines Market –Trends
4. GLOBAL CHILDHOOD VACCINES MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL CHILDHOOD VACCINES MARKET, BY TREATMENT TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. Inactivated Vaccines
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Attenuated Vaccines
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Toxoid Vaccines
5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Subunit Vaccines
5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Conjugate Vaccines
5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. GLOBAL CHILDHOOD VACCINES MARKET, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
6.1. Oral
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Intramuscular
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Intradermal
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Subcutaneous
6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Intranasal
6.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. GLOBAL CHILDHOOD VACCINES MARKET, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
7.1. Diphtheria
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Pertussis
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Tetanus
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Polio
7.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Measles
7.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Hepatitis-B
7.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.6.3. Market Opportunity Analysis
7.7. Others
7.7.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.7.3. Market Opportunity Analysis
8. GLOBAL CHILDHOOD VACCINES MARKET FORECAST, BY COMPOSITION, 2012 - 2016 AND FORECAST, 2017 – 2023
8.1. Mono Vaccines
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Combination Vaccines
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
9. GLOBAL CHILDHOOD VACCINES MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023
9.1. Hospitals
9.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Clinics
9.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Vaccination Centres
9.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
10. GLOBAL CHILDHOOD VACCINES MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1. North America
10.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.1.3. Market Opportunity Analysis
10.2. Europe
10.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.2.3. Market Opportunity Analysis
10.3. Asia-Pacific
10.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.3.3. Market Opportunity Analysis
10.4. Latin America
10.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.4.3. Market Opportunity Analysis
10.5. Middle East and Africa
10.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.5.3. Market Opportunity Analysis
10.6. Global Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Region, 2017 – 2023
11. NORTH AMERICA CHILDHOOD VACCINES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1. Vaccine Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Inactivated Vaccines
11.1.2. Attenuated Vaccines
11.1.3. Toxoid Vaccines
11.1.4. Subunit Vaccines
11.1.5. Conjugate Vaccines
11.1.6. Others
11.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Oral
11.2.2. Intramuscular
11.2.3. Intradermal
11.2.4. Subcutaneous
11.2.5. Intranasal
11.3. Application Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Diphtheria
11.3.2. Pertussis
11.3.3. Tetanus
11.3.4. Polio
11.3.5. Measles
11.3.6. Hepatitis-B
11.3.7. Others
11.4. Composition Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Mono Vaccines
11.4.2. Combinition Vaccines
11.5. End-User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Vaccination Centres
11.6. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.6.1. U.S.
11.6.2. Canada
11.7. North America Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2017 – 2023
11.8. North America Childhood Vaccines Market Dynamics – Trends
12. EUROPE CHILDHOOD VACCINES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1. Vaccine Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Inactivated Vaccines
12.1.2. Attenuated Vaccines
12.1.3. Toxoid Vaccines
12.1.4. Subunit Vaccines
12.1.5. Conjugate Vaccines
12.1.6. Others
12.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Oral
12.2.2. Intramuscular
12.2.3. Intradermal
12.2.4. Subcutaneous
12.2.5. Intranasal
12.3. Application Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Diphtheria
12.3.2. Pertussis
12.3.3. Tetanus
12.3.4. Polio
12.3.5. Measles
12.3.6. Hepatitis-B
12.3.7. Others
12.4. Composition Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Mono Vaccines
12.4.2. Combinition Vaccines
12.5. End-User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Vaccination Centres
12.6. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.6.1. Germany
12.6.2. UK
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Russia
12.6.7. Poland
12.6.8. Rest of Europe
12.7. Europe Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2017 – 2023
12.8. Europe Childhood Vaccines Market Dynamics – Trends
13. ASIA-PACIFIC CHILDHOOD VACCINES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
13.1. Vaccine Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Inactivated Vaccines
13.1.2. Attenuated Vaccines
13.1.3. Toxoid Vaccines
13.1.4. Subunit Vaccines
13.1.5. Conjugate Vaccines
13.1.6. Others
13.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Oral
13.2.2. Intramuscular
13.2.3. Intradermal
13.2.4. Subcutaneous
13.2.5. Intranasal
13.3. Application Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Diphtheria
13.3.2. Pertussis
13.3.3. Tetanus
13.3.4. Polio
13.3.5. Measles
13.3.6. Hepatitis-B
13.3.7. Others
13.4. Composition Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Mono Vaccines
13.4.2. Combinition Vaccines
13.5. End-User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Vaccination Centres
13.6. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. ASEAN
13.6.5. Australia & New Zealand
13.6.6. Rest of Asia-Pacific
13.7. Asia-Pacific Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2017 – 2023
13.8. Asia-Pacific Childhood Vaccines Market Dynamics – Trends
14. LATIN AMERICA CHILDHOOD VACCINES MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
14.1. Vaccine Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Inactivated Vaccines
14.1.2. Attenuated Vaccines
14.1.3. Toxoid Vaccines
14.1.4. Subunit Vaccines
14.1.5. Conjugate Vaccines
14.1.6. Others
14.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Oral
14.2.2. Intramuscular
14.2.3. Intradermal
14.2.4. Subcutaneous
14.2.5. Intranasal
14.3. Application Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Diphtheria
14.3.2. Pertussis
14.3.3. Tetanus
14.3.4. Polio
14.3.5. Measles
14.3.6. Hepatitis-B
14.3.7. Others
14.4. Composition Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Mono Vaccines
14.4.2. Combinition Vaccines
14.5. End-User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Vaccination Centres
14.6. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Argentina
14.6.4. Venezuela
14.6.5. Rest of Latin America
14.7. Latin America Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2017 – 2023
14.8. Latin America Childhood Vaccines Market Dynamics – Trends
15. MIDDLE EAST AND AFRICA CHILDHOOD VACCINES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
15.1. Vaccine Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
15.1.1. Inactivated Vaccines
15.1.2. Attenuated Vaccines
15.1.3. Toxoid Vaccines
15.1.4. Subunit Vaccines
15.1.5. Conjugate Vaccines
15.1.6. Others
15.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.2.1. Oral
15.2.2. Intramuscular
15.2.3. Intradermal
15.2.4. Subcutaneous
15.2.5. Intranasal
15.3. Application Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.3.1. Diphtheria
15.3.2. Pertussis
15.3.3. Tetanus
15.3.4. Polio
15.3.5. Measles
15.3.6. Hepatitis-B
15.3.7. Others
15.4. Composition Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.4.1. Mono Vaccines
15.4.2. Combinition Vaccines
15.5. End-User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Vaccination Centres
15.6. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
15.6.1. Gulf Cooperation Council (GCC) Countries
15.6.2. Israel
15.6.3. South Africa
15.6.4. Rest of MEA
15.7. MEA Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2017 – 2023
15.8. MEA Childhood Vaccines Market Dynamics – Trends
16. COMPETITION LANDSCAPE
16.1. Strategic Dashboard of Top Market Players
16.2. Company Profiles (Introduction, Financial Analysis, Treatment Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
16.2.1. AstraZeneca (UK)
16.2.2. Bayer AG (Germany)
16.2.3. Daiichi Sankyo Company Ltd (Japan)
16.2.4. Eisai Co Ltd (Japan)
16.2.5. GlaxoSmithKline Plc. (UK)
16.2.6. Grupo Praxis Pharmaceutical SA (Spain)
16.2.7. KaloBios Pharmaceuticals, Inc. (U.S.)
16.2.8. Kancera AB (Sweden)
16.2.9. Novartis AG (Switzerland)
16.2.10. Laboratorio Elea S.A.C.I.F. y A (Argentina)
16.2.11. Oblita Therapeutics BVBA (Belgium)
16.2.12. Sanofi (France
17. RESEARCH METHODOLOGY
18. KEY ASSUMPTIONS AND ACRONYMS
